<DOC>
	<DOCNO>NCT01474538</DOCNO>
	<brief_summary>This study provide information use insulin lispro insulin aspart insulin pump participant type 2 diabetes .</brief_summary>
	<brief_title>Safety Efficacy Study Insulin Lispro Versus Insulin Aspart Participants With Type 2 Diabetes Insulin Pump Therapy</brief_title>
	<detailed_description>This study provide clinical information use insulin lispro continuous subcutaneous insulin infusion ( CSII ) participant type 2 diabetes . This study design allow comparison 2 rapid-acting insulin analog , regard efficacy safety , use pump insulin therapy participant population . Each participant randomize 1 2 sequence group 1:1 ratio randomization stratify accord screen A1C ( less equal 8.0 % great 8.0 % ) thiazolidinedione ( TZD ) use ( yes ) . The study design include follow period : Screening/Randomization , Treatment Period 1 ( 16 week ) , Treatment Period 2 ( 16 week ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Have type 2 diabetes ( per World Health Organization [ WHO ] Classification Diabetes ) Have treat CSII therapy use rapidacting analog previous 6 month Have screen A1C le equal 9.0 % ( low limit A1C ) Have body mass index ( BMI ) less 45 kilograms/square meter ( kg/mÂ² ) screen Have history stable body weight ( vary great 10 % least 3 month prior screen ) For participant oral antidiabetes medication ( OAMs ) : must stable dose OAMs , label use insulin , least 3 month prior study entry Have severe insulin resistance [ require great 2 units/kilogram/day ( U/kg/day ) insulin ] Are take take within last 3 month , antihyperglycemic medication approve use insulin , injectable noninsulin antihyperglycemic medication , contraindication current antihyperglycemic medication Have serum creatinine great equal 2 milligrams/deciliter ( mg/dL ) metformin ; know metabolic lactic acidosis ; condition associate hypoperfusion , hypoxemia , dehydration , sepsis ; and/or radiologic contrast study within 48 hour prior study entry Are receive chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical , intraocular , intraarticular , inhaled preparation ) receive therapy within 2 week immediately screen Have 1 episode hypoglycemia ( define require assistance third party due disable hypoglycemia ) within 6 month prior entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>diabetes</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>insulin pump</keyword>
	<keyword>continuous subcutaneous insulin infusion</keyword>
	<keyword>CSII</keyword>
	<keyword>A1C</keyword>
</DOC>